Financial Performance - The company's revenue for Q1 2025 was ¥737,792,254.37, a decrease of 8.59% compared to ¥807,154,893.30 in the same period last year[5] - Net profit attributable to shareholders was ¥91,425,130.39, down 9.68% from ¥101,221,564.63 year-on-year[5] - Basic earnings per share were ¥0.45, a decline of 10.00% from ¥0.50 in the same period last year[5] - Net profit for the period was ¥91,572,859.16, down from ¥101,039,013.17, reflecting a decrease of approximately 9.5% year-over-year[22] - Total operating revenue decreased to ¥737,792,254.37 from ¥807,154,893.30, representing a decline of approximately 8.6% year-over-year[21] - Total operating costs decreased to ¥646,327,861.69 from ¥676,812,278.56, a reduction of about 4.5% year-over-year[21] Cash Flow - The net cash flow from operating activities decreased by 51.82%, amounting to ¥110,058,277.19 compared to ¥228,412,107.91 in the previous year[5] - Operating cash inflow for the current period was $791,876,819.30, a decrease of 5.6% from $838,733,918.37 in the previous period[25] - Total cash outflow from operating activities was $681,818,542.11, an increase of 11.7% from $610,321,810.46 in the previous period[25] - Cash received from sales of goods and services was $748,166,889.53, down from $809,679,385.05, indicating a decline of 7.6%[25] - Cash received from tax refunds increased to $2,065,452.90, up from $1,217,481.61, representing a growth of 69.9%[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,418,333,542.84, a slight decrease of 0.07% from ¥6,422,666,712.07 at the end of the previous year[5] - The company's total current assets amount to 3,913,564,439.07 RMB, slightly decreasing from 3,925,489,622.21 RMB at the beginning of the period[17] - Total liabilities decreased to ¥1,509,617,533.83 from ¥1,620,317,541.89, a reduction of approximately 6.8% year-over-year[19] - The total non-current assets are valued at 1,894,000,000 RMB, with fixed assets accounting for 1,480,634,778.64 RMB[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,428, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Changsha Medical Investment Co., Ltd., holds 40.69% of shares, amounting to 85,079,923 shares, with 8,010,000 shares pledged[13] - The top ten shareholders collectively hold a significant portion of the company's equity, with the top three shareholders alone accounting for over 50%[13] - The company has not reported any changes in the shareholding structure of the top ten shareholders due to margin trading activities[14] Investment and Expenses - The company reported a significant increase in investment income, which rose by 2492.20% to ¥10,327,107.82 from a loss of ¥431,699.64 in the previous year[10] - Management expenses increased by 37.52% to ¥40,596,125.82, primarily due to higher costs associated with the acquisition of a company[10] - Research and development expenses were ¥18,836,066.75, down from ¥22,369,153.88, indicating a decrease of about 15.5% year-over-year[21] - The company experienced a 33.90% increase in net cash outflow from investing activities, totaling -¥94,905,406.71, attributed to increased purchases of financial products[12] Equity and Minority Interests - The company’s total equity attributable to shareholders increased by 2.02% to ¥4,893,677,663.77 from ¥4,796,596,352.25 at the end of the previous year[5] - The company reported a 161.41% increase in minority interests, reaching ¥15,038,345.24, primarily due to the acquisition of a company[9] - The equity attributable to shareholders of the parent company increased to ¥4,893,677,663.77 from ¥4,796,596,352.25, an increase of about 2.0% year-over-year[19]
可孚医疗(301087) - 2025 Q1 - 季度财报